Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
Johnson & Johnson (NYSE:JNJ) is reportedly negotiating with plaintiffs' lawyers who have opposed its proposed $6.48 billion settlement over claims that its talc-based baby powder and other products cause cancer.
據報道，強生公司（NYSE:JNJ）正在與反對其涉嫌滑石粉嬰兒爽身粉及其其他產品致癌的索賠案的原告律師進行談判，以解決預計68.4億美元的和解協議。
What Happened: Per a Reuters report, the New Brunswick, New Jersey-based company aims to resolve the remaining holdouts as it seeks to finalize the deal through the bankruptcy of a subsidiary following setbacks in federal courts.
據路透社報道，這家總部位於新澤西州新不倫瑞克的公司計劃通過其子公司的破產解決剩餘的訴訟問題，以便終結協議。公司在聯邦法院遭遇挫折之後希望解決剩餘的持不同意見的人。
Johnson & Johnson has temporarily paused the voting process to gather more votes from plaintiffs who have been resistant.
強生公司已暫停表決過程，以收集更多持反對意見的索賠人的票數。
Also Read: JohnsonA & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave.
還閱讀：強生公司達成17億美元交易收購心臟技術創新公司V-Wave。
"We have agreed to a short extension of the certification timeline," said Erik Haas, Johnson & Johnson's worldwide vice president of litigation, said Friday. "This will allow these plaintiffs' attorneys time to speak to their claimants to now consider supporting the plan."
強生公司全球訴訟副總裁埃裏克·哈斯（Erik Haas）表示：「我們已經同意將認證時間表短暫延長。這將使這些原告律師有時間與他們的原告溝通，考慮支持該計劃。」
The company plans to place a subsidiary into bankruptcy if at least 75% of the claimants agree to the settlement proposal.
如果至少有75%的索賠人同意和解提議，該公司計劃將一個子公司放入破產。
The settlement would resolve all current talc-related lawsuits and prevent future cases that allege that Johnson & Johnson's products cause ovarian cancer and other illnesses.
該和解協議將解決所有與滑石粉相關的訴訟，並防止未來聲稱強生公司產品導致卵巢癌和其他疾病的案件。
Attorney Andy Birchfield, a key opponent of Johnson & Johnson's bankruptcy strategy, expressed openness to further negotiations but emphasized that he remains ready to challenge another Chapter 11 filing if necessary.
反對強生公司破產策略的主要對手律師安迪·伯奇菲爾德（Andy Birchfield）表示願意進行進一步的談判，但強調如果有必要他仍準備挑戰另一起第11章破產申請。
Why It Maters: Johnson & Johnson is currently facing lawsuits from over 62,000 plaintiffs who claim that the company's talc products were contaminated with asbestos, leading to cancer diagnoses.
重要性：強生公司目前面臨來自超過62,000名原告的訴訟，他們聲稱該公司的滑石粉產品被石棉污染，導致患癌症的診斷。
In May, Johnson & Johnson announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ovarian cancer arising from cosmetic talc litigation.
今年5月，強生公司宣佈打算進行一項64.75億美元的和解，以解決與化妝用滑石粉訴訟相關的衆多卵巢癌訴訟。
The company has already paid approximately $5 billion to settle talc-related claims, including those involving mesothelioma and other cancers and allegations of illegal marketing practices by U.S. states.
該公司已經支付了約50億美元來解決涉及滑石粉的索賠，包括那些涉及間皮瘤和其他癌症以及美國各州非法營銷行爲的指控。
Reuters cited internal documents and memos, including deposition and past trial testimonies, that show how Johnson & Johnson withheld info on the trace amounts of asbestos from regulators and the public for decades.
路透社引用內部文件和備忘錄，包括證言和過去的審判證詞，顯示強生公司幾十年來對石棉微量元素的信息對監管機構和公衆進行了隱瞞。
Price Action: JNJ closed at $164.13 on Friday.
股價走勢：JNJ上週五收盤報164.13美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
- 西門子醫療將以2.2億美元的價格收購諾華診斷業務，以加強其癌症掃描業務。